Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials

Background. Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan-xian, Yang, Qiong, Kuang, Jun-jie, Chen, Shi-yu, Wei, Ying, Jiang, Zhi-min, Xie, De-rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/
https://www.ncbi.nlm.nih.gov/pubmed/24971091
http://dx.doi.org/10.1155/2014/594930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/
https://www.ncbi.nlm.nih.gov/pubmed/24971091
http://dx.doi.org/10.1155/2014/594930

Ejemplares similares